Alces Bioworks, Inc.
@alcesbioworks.bsky.social
Alces Bioworks uses revolutionary protein design technologies to create superior affinity reagents for its customers. Affinity reagents made better and faster. https://www.alcesbioworks.com
Reposted by Alces Bioworks, Inc.
High-resolution data from the GHGSat satellite constellation reveal facility-level methane emissions at thousands of individual sites worldwide, according to a new study in Science. The findings provide a far more detailed picture of methane emissions from the energy sector. https://scim.ag/48Q70rw
December 17, 2025 at 8:33 PM
High-resolution data from the GHGSat satellite constellation reveal facility-level methane emissions at thousands of individual sites worldwide, according to a new study in Science. The findings provide a far more detailed picture of methane emissions from the energy sector. https://scim.ag/48Q70rw
Al The-Lab-Moose wishes you a peaceful and joyful holiday season 🎄 🕎 ❄️ 🎅
December 17, 2025 at 8:33 PM
Al The-Lab-Moose wishes you a peaceful and joyful holiday season 🎄 🕎 ❄️ 🎅
New FAQ on the Alces Bioworks website - why use Alceins instead of antibodies to analyze or purify proteins of interest?
alcesbioworks.com/faq/
alcesbioworks.com/faq/
Custom Affinity Reagents & Protein Design Services | Alces Bioworks
Discover Alces Bioworks’ custom affinity reagent and protein design services. We create fast, stable, animal-free Alceins™ as better alternatives to monoclonal antibodies.
alcesbioworks.com
December 12, 2025 at 2:06 PM
New FAQ on the Alces Bioworks website - why use Alceins instead of antibodies to analyze or purify proteins of interest?
alcesbioworks.com/faq/
alcesbioworks.com/faq/
Reposted by Alces Bioworks, Inc.
TIME recently invited me to share my perspective on the past year in AI development.
We've seen major growth in AI capabilities & risks, but as
@law-zero.bsky.social continues its research, I'm increasingly confident that technical solutions are possible to make AI safer.
time.com/7339687/yosh...
We've seen major growth in AI capabilities & risks, but as
@law-zero.bsky.social continues its research, I'm increasingly confident that technical solutions are possible to make AI safer.
time.com/7339687/yosh...
We're Not Ready for AI's Risks
It’s possible that we’re nearing the limits of our current approach to frontier AI, says Yoshua Bengio
time.com
December 11, 2025 at 6:55 PM
TIME recently invited me to share my perspective on the past year in AI development.
We've seen major growth in AI capabilities & risks, but as
@law-zero.bsky.social continues its research, I'm increasingly confident that technical solutions are possible to make AI safer.
time.com/7339687/yosh...
We've seen major growth in AI capabilities & risks, but as
@law-zero.bsky.social continues its research, I'm increasingly confident that technical solutions are possible to make AI safer.
time.com/7339687/yosh...
Reposted by Alces Bioworks, Inc.
Nature research paper: Agonists for cytosolic bacterial receptor ALPK1 induce antitumour immunity
go.nature.com/454ALUu
go.nature.com/454ALUu
Agonists for cytosolic bacterial receptor ALPK1 induce antitumour immunity - Nature
The ALPK1 agonist UDSP-Hep stimulates tumour-cell antigen presentation, macrophage–DC cross-priming and differentiation of protective memory T cells.
go.nature.com
December 12, 2025 at 11:03 AM
Nature research paper: Agonists for cytosolic bacterial receptor ALPK1 induce antitumour immunity
go.nature.com/454ALUu
go.nature.com/454ALUu
Reposted by Alces Bioworks, Inc.
oh, this is nice: x.com/proteinbase/.... only a few lines of code…
December 3, 2025 at 7:26 PM
oh, this is nice: x.com/proteinbase/.... only a few lines of code…
Reposted by Alces Bioworks, Inc.
Stephen Witt’s The Thinking Machine, about the rise of Nvidia and its hard-driving leader Jensen Huang, has won the 2025 Financial Times and Schroders Business Book of the Year Award. on.ft.com/49VjnVG
December 3, 2025 at 10:00 PM
Stephen Witt’s The Thinking Machine, about the rise of Nvidia and its hard-driving leader Jensen Huang, has won the 2025 Financial Times and Schroders Business Book of the Year Award. on.ft.com/49VjnVG
Reposted by Alces Bioworks, Inc.
An anti-allergy vaccine protects mice from anaphylaxis for as long as one year, mRNA-ferrying nanoparticles treat fatty liver disease in animals and potentiate immunotherapy against liver tumors, and more this week in #ScienceTranslationalMedicine. https://scim.ag/3XxHAdi
December 3, 2025 at 10:12 PM
An anti-allergy vaccine protects mice from anaphylaxis for as long as one year, mRNA-ferrying nanoparticles treat fatty liver disease in animals and potentiate immunotherapy against liver tumors, and more this week in #ScienceTranslationalMedicine. https://scim.ag/3XxHAdi
Reposted by Alces Bioworks, Inc.
AlphaFold DB v6 (synced with UniProt 2025_03) is live! Here are the details:
Totals v4 → v6: 241,070,489 entries.
Since v4: +65,711,653 added, 39,324,993 removed, 276,539 changed (in sequence), 175,082,297 unchanged (metadata refresh, relabelled v6). Details 👇
Totals v4 → v6: 241,070,489 entries.
Since v4: +65,711,653 added, 39,324,993 removed, 276,539 changed (in sequence), 175,082,297 unchanged (metadata refresh, relabelled v6). Details 👇
October 21, 2025 at 1:00 PM
AlphaFold DB v6 (synced with UniProt 2025_03) is live! Here are the details:
Totals v4 → v6: 241,070,489 entries.
Since v4: +65,711,653 added, 39,324,993 removed, 276,539 changed (in sequence), 175,082,297 unchanged (metadata refresh, relabelled v6). Details 👇
Totals v4 → v6: 241,070,489 entries.
Since v4: +65,711,653 added, 39,324,993 removed, 276,539 changed (in sequence), 175,082,297 unchanged (metadata refresh, relabelled v6). Details 👇
Reposted by Alces Bioworks, Inc.
Scientists have designed an interleukin-21 mimic with increased stability and capacity to induce more potent antitumor activity than the native protein, which could inform improved #immunotherapies.
Learn more in #ScienceImmunology: https://scim.ag/47jQLSW
Learn more in #ScienceImmunology: https://scim.ag/47jQLSW
Design of a potent interleukin-21 mimic for cancer immunotherapy
A de novo IL-21 mimic, 21h10, exhibits improved stability and potent antitumor activity in vivo compared with native IL-21.
scim.ag
October 21, 2025 at 3:08 PM
Scientists have designed an interleukin-21 mimic with increased stability and capacity to induce more potent antitumor activity than the native protein, which could inform improved #immunotherapies.
Learn more in #ScienceImmunology: https://scim.ag/47jQLSW
Learn more in #ScienceImmunology: https://scim.ag/47jQLSW
Reposted by Alces Bioworks, Inc.
Join us in Room 181, Building 68 @mit.edu on October 22nd 2025 @ 7pm EDT to see @grocklin.bsky.social present a mind blowing amount of data and learn what becomes possible at this scale
"Predicting protein folding stability and aggregation propensity using large-scale experiments"
bpdmc.org
"Predicting protein folding stability and aggregation propensity using large-scale experiments"
bpdmc.org
schedule
introduction and membership
Boston Protein Design and Modeling Club (BPDMC) is a community of computational protein engineers and modelers from both academia and industry. While we are based in Boston...
bpdmc.org
October 17, 2025 at 8:27 PM
Join us in Room 181, Building 68 @mit.edu on October 22nd 2025 @ 7pm EDT to see @grocklin.bsky.social present a mind blowing amount of data and learn what becomes possible at this scale
"Predicting protein folding stability and aggregation propensity using large-scale experiments"
bpdmc.org
"Predicting protein folding stability and aggregation propensity using large-scale experiments"
bpdmc.org
Reposted by Alces Bioworks, Inc.
Success rates for Europe’s leading research grants are declining as a surge in applications far outweighs the funds available
go.nature.com/479Sni6
go.nature.com/479Sni6
Is academic research becoming too competitive? Nature examines the data
Applications for European research grants increased in 2025. Scientists say they’re feeling the competition.
go.nature.com
October 17, 2025 at 10:12 AM
Success rates for Europe’s leading research grants are declining as a surge in applications far outweighs the funds available
go.nature.com/479Sni6
go.nature.com/479Sni6
Nabla expects first-in-human data from its AI-designed molecules within one to two years, according to Reuters.
Takeda Pharmaceuticals and Nabla Bio, a start-up focused on designing de novo proteins with artificial intelligence, have signed a second round of collaboration.
cen.acs.org/pharmaceutic... #chemsky 🧪
cen.acs.org/pharmaceutic... #chemsky 🧪
AI-based protein discovery start-up strikes a second deal with Takeda
Nabla Bio's platform is becoming popular with big pharma companies
cen.acs.org
October 17, 2025 at 2:28 PM
Nabla expects first-in-human data from its AI-designed molecules within one to two years, according to Reuters.
Reposted by Alces Bioworks, Inc.
On course to end new HIV cases in the UK by 2030.
First injection to stop HIV approved
The shot, given six times a year or every other month, is an alternative to taking daily pills to protect against ever catching the virus.
www.bbc.com
October 17, 2025 at 6:10 AM
On course to end new HIV cases in the UK by 2030.
Reposted by Alces Bioworks, Inc.
🚨Our paper is out! 🥳
Hijacking a bacterial ABC transporter for efficient genetic code expansion.
Many congrats to everyone involved - a multi-year effort led by @taruniype.bsky.social @maxfottner.bsky.social
www.nature.com/articles/s41...
it all started years ago with a failed experiment
🧵👇 1/9
Hijacking a bacterial ABC transporter for efficient genetic code expansion.
Many congrats to everyone involved - a multi-year effort led by @taruniype.bsky.social @maxfottner.bsky.social
www.nature.com/articles/s41...
it all started years ago with a failed experiment
🧵👇 1/9
Hijacking a bacterial ABC transporter for genetic code expansion - Nature
Bacterial ATP-binding cassette (ABC) transporters can be utilized and engineered to transport non-canonical amino acids into Escherichia coli for highly efficient synthesis of proteins with novel func...
www.nature.com
October 16, 2025 at 2:06 PM
🚨Our paper is out! 🥳
Hijacking a bacterial ABC transporter for efficient genetic code expansion.
Many congrats to everyone involved - a multi-year effort led by @taruniype.bsky.social @maxfottner.bsky.social
www.nature.com/articles/s41...
it all started years ago with a failed experiment
🧵👇 1/9
Hijacking a bacterial ABC transporter for efficient genetic code expansion.
Many congrats to everyone involved - a multi-year effort led by @taruniype.bsky.social @maxfottner.bsky.social
www.nature.com/articles/s41...
it all started years ago with a failed experiment
🧵👇 1/9
A new blog post on our website: how to measure binding affinity of an Alcein!
alcesbioworks.com/how-we-measu...
alcesbioworks.com/how-we-measu...
September 26, 2025 at 6:17 PM
A new blog post on our website: how to measure binding affinity of an Alcein!
alcesbioworks.com/how-we-measu...
alcesbioworks.com/how-we-measu...
Reposted by Alces Bioworks, Inc.
At the Berlin node of a global hackathon, teams raced to develop artificial intelligence tools to accelerate the design of drugs and materials. https://scim.ag/3VuZyvR
Researchers customize AI tools at global ‘hackathon’
More than 1200 scientists and developers explore how large language models can be applied to materials science and chemistry
www.science.org
September 22, 2025 at 11:12 PM
At the Berlin node of a global hackathon, teams raced to develop artificial intelligence tools to accelerate the design of drugs and materials. https://scim.ag/3VuZyvR
Reposted by Alces Bioworks, Inc.
Nvidia to invest up to $100bn in OpenAI on.ft.com/4mxtu5N
Nvidia to invest up to $100bn in OpenAI
Partnership will support massive build-out of data centres for artificial intelligence
on.ft.com
September 22, 2025 at 4:43 PM
Nvidia to invest up to $100bn in OpenAI on.ft.com/4mxtu5N
Reposted by Alces Bioworks, Inc.
New review on AI and protein design...
Code to complex: AI-driven de novo binder design: Structure www.cell.com/structure/fu...
Code to complex: AI-driven de novo binder design: Structure www.cell.com/structure/fu...
Code to complex: AI-driven de novo binder design
In this review, Fox et al. discuss how artificial intelligence has transformed our
ability to design new-to-nature proteins that bind target proteins with high affinity
and specificity. The authors de...
www.cell.com
September 5, 2025 at 1:30 PM
New review on AI and protein design...
Code to complex: AI-driven de novo binder design: Structure www.cell.com/structure/fu...
Code to complex: AI-driven de novo binder design: Structure www.cell.com/structure/fu...
New review on AI and protein design...
Code to complex: AI-driven de novo binder design: Structure www.cell.com/structure/fu...
Code to complex: AI-driven de novo binder design: Structure www.cell.com/structure/fu...
Code to complex: AI-driven de novo binder design
In this review, Fox et al. discuss how artificial intelligence has transformed our
ability to design new-to-nature proteins that bind target proteins with high affinity
and specificity. The authors de...
www.cell.com
September 5, 2025 at 1:30 PM
New review on AI and protein design...
Code to complex: AI-driven de novo binder design: Structure www.cell.com/structure/fu...
Code to complex: AI-driven de novo binder design: Structure www.cell.com/structure/fu...
Reposted by Alces Bioworks, Inc.
We’re thrilled to announce that Alces Bioworks has joined the NVIDIA Inception program!
This supports our mission to create for our customers superior affinity reagents we call Alceins™.
#NVIDIAInception #AI #BiotechInnovation
This supports our mission to create for our customers superior affinity reagents we call Alceins™.
#NVIDIAInception #AI #BiotechInnovation
August 20, 2025 at 1:29 PM
We’re thrilled to announce that Alces Bioworks has joined the NVIDIA Inception program!
This supports our mission to create for our customers superior affinity reagents we call Alceins™.
#NVIDIAInception #AI #BiotechInnovation
This supports our mission to create for our customers superior affinity reagents we call Alceins™.
#NVIDIAInception #AI #BiotechInnovation
We’re thrilled to announce that Alces Bioworks has joined the NVIDIA Inception program!
This supports our mission to create for our customers superior affinity reagents we call Alceins™.
#NVIDIAInception #AI #BiotechInnovation
This supports our mission to create for our customers superior affinity reagents we call Alceins™.
#NVIDIAInception #AI #BiotechInnovation
August 20, 2025 at 1:29 PM
We’re thrilled to announce that Alces Bioworks has joined the NVIDIA Inception program!
This supports our mission to create for our customers superior affinity reagents we call Alceins™.
#NVIDIAInception #AI #BiotechInnovation
This supports our mission to create for our customers superior affinity reagents we call Alceins™.
#NVIDIAInception #AI #BiotechInnovation
